Near-infrared photodynamic therapy using second harmonic generation nanoparticles and visible light reactive photosensitizers

By using the second harmonic to generate nanoparticles, nonionic water-soluble spacers and water-insoluble photosensitizers in photodynamic therapy, the problems of low excitation efficiency and spectral mismatch of photosensitizers are solved, and the biological tissues are achieved Photodynamic therapy that utilizes near-infrared light in medium and efficiently improves therapeutic effect and selectivity.

CN119031935AInactive Publication Date: 2024-11-26ARIEL SCI INNOVATIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033227.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-14
Filing Date
2023-02-14
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing photodynamic therapies have low excitation efficiency of photosensitizers in the target area, and the absorption spectrum of conventional photosensitizers does not meet the maximum light penetration depth range of biological tissues, making it difficult to effectively use the near-infrared window for treatment.

Method used

Develop a nanoparticle composition including secondary harmonic generating nanoparticles, nonionic water-soluble spacers and water-insoluble photosensitizers, by adjusting the molecular weight and type of spacers, so that SHG particles and photosensitizers can be used to enable SHG particles and photosensitizers at 360 nm and It is excitated multiple times within the 450nm range and uses near-infrared light-induced photodynamic therapy.

Benefits of technology

It improves the treatment efficiency and selectivity of photodynamic therapy in the target area, avoids photobleaching, enhances the response to near-infrared light, and achieves a deeper therapeutic effect in biological tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119031935A_ABST
    Figure CN119031935A_ABST
Patent Text Reader

Abstract

The present invention relates to second harmonic generating particles comprising photosensitizers separated by non-ionic water-soluble spacers, methods of manufacture and uses thereof, such as for photodynamic therapy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. provisional patent application serial number 63 / 309,652, filed on February 14, 2022, entitled “NEAR-INFRARED PHOTODYNAMICTHERAPY USING SECOND HARMONIC GENERATION NANOPARTICLE AND VISIBLE LIGHTREACTIVE PHOTOSENSITIZER,” the contents of which are incorporated by reference in their entirety. Technical Field

[0003] The present invention is in the field of nanoparticles comprising a photosensitizer in operable communication with second harmonic generation particles, for example for use in photodynamic therapy. Background Art

[0004] Photodynamic therapy (PDT) uses light and chemicals called photosensitizers (PS) to generate molecular oxygen and stimulate cell death. This phenomenon is known as phototoxicity. This promising approach has been developed for a variety of applications, including microbial inactivation and treatment of infections. PDT offers advantages over conventional therapies as a treatment method due to its dual specificity: 1) PS is targeted to specific locations in cells or tissues; and 2) irradiation regimens can be spatially confined to allow selective treatment. The generation of reactive oxygen species (ROS) in individual cells can lead to irreversible damage and cell death. PDT directly initiates an apoptotic response in target cells without the need for intermediate signaling pathways, as is the case in drug-resistant tumor cells.

[0005] Second harmonic generation (SHG) is a nonlinear optical effect in which two photons are absorbed and converted to emit a single photon with doubled energy (and half the wavelength) when passing through certain materials. As a nonparametric process, the SHG effect can be tuned to achieve localized excitation. Because SHG does not involve energy loss, photobleaching can be effectively avoided. This suggests that SHG can be effectively used to generate specific biological responses in targeted applications without affecting surrounding healthy tissue.

[0006] The absorption spectrum of conventionally used PS molecules is within the 400-750 nm range (visible spectrum). However, the maximum penetration depth of light into tissue is within the 650-950 nm range, known as the near-infrared (NIR) window. Therefore, it is necessary to develop methods to induce PDT in target areas of the subject's body by utilizing excitation wavelengths in the NIR window. Summary of the Invention

[0007] The following embodiments and various aspects thereof are described and illustrated in conjunction with systems, tools and methods, which are exemplary and illustrative and do not limit the scope thereof.

[0008] In one aspect, a composition comprising a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises (i) a second harmonic generation (SHG) particle, (ii) a non-ionic water-soluble spacer, and (iii) a photosensitizer; wherein: the SHG particle is configured to emit a plurality of photons within a wavelength range between 360 nm and 450 nm; the photosensitizer is a water-insoluble photosensitizer characterized by an absorbance range that at least partially overlaps the wavelength range; and wherein the photosensitizer is in operative communication with the SHG particle to allow excitation of the photosensitizer by the plurality of photons.

[0009] In some embodiments, the operable communication comprises a distance between the SHG particles and the photosensitizer that is suitable for multiple photons to excite the photosensitizer.

[0010] In some embodiments, the SHG particles and the photosensitizer are separated by a non-ionic water-soluble spacer; and wherein the distance is predetermined by the molecular weight of the water-soluble spacer.

[0011] In some embodiments, the molecular weight is between 50 Da and 1000 Da.

[0012] In some embodiments, the water-soluble spacer comprises ethylene glycol (EG), EG oligomers, or polyethylene glycol (PEG).

[0013] In some embodiments, the SHG nanoparticles are selected from barium titanate, lithium niobate, and potassium niobate, or any combination thereof.

[0014] In some embodiments, the photosensitizer is selected from a curcuminoid photosensitizer, a porphyrin photosensitizer, a phthalocyanine photosensitizer, or any combination thereof.

[0015] In some embodiments, the porphyrin-based photosensitizer is protoporphyrin IX, including any salt thereof.

[0016] In another aspect, a composition is provided, comprising a plurality of nanoparticles, wherein each of the plurality of nanoparticles has a core in contact with a shell; wherein the core comprises an SHG particle configured to emit a plurality of photons within a wavelength range between 360 nm and 450 nm; the shell comprises a water-soluble non-ionic spacer and a photosensitizer; and the photosensitizer is a water-insoluble photosensitizer characterized by an absorbance range that at least partially overlaps the wavelength range; the photosensitizer is separated from the core by the water-soluble non-ionic spacer to allow the plurality of photons to excite the photosensitizer.

[0017] In some embodiments, the photosensitizer is selected from curcuminoid photosensitizers or porphyrin photosensitizers, and any combination thereof.

[0018] In some embodiments, the porphyrin-based photosensitizer is protoporphyrin IX, including any salt thereof.

[0019] In some embodiments, the average molecular weight of the water-soluble nonionic spacer is between 50 Da and 1000 Da.

[0020] In some embodiments, the water-soluble nonionic spacer comprises ethylene glycol (EG), EG oligomers, or polyethylene glycol (PEG).

[0021] In some embodiments, the weight ratio of the photosensitizer to the nonionic water-soluble spacer in the composition is between 1:150 and 1:3500.

[0022] In some embodiments, the weight ratio of photosensitizer to SHG particles in the composition is between 5:1 and 1:5.

[0023] In some embodiments, the plurality of nanoparticles is adapted to induce a photodynamic response in a cell.

[0024] In another aspect, a composition comprising a plurality of nanoparticles is provided, wherein each of the plurality of nanoparticles comprises: (i) SHG particles, (ii) PEG, and (iii) a photosensitizer; wherein: the SHG particles and the photosensitizer are separated by the PEG; the photosensitizer is a water-insoluble photosensitizer characterized by an absorbance at a wavelength in the range of approximately 360 nm and 450 nm; the SHG particles are barium titanate; and the PEG is characterized by an average molecular weight between 50 Da and 1000 Da.

[0025] In some embodiments, the photosensitizer is selected from protoporphyrin IX and curcumin, including any salts thereof; and wherein the PEG is characterized by an average molecular weight between about 280 Da and 320 Da.

[0026] In another aspect, a pharmaceutical composition is provided, comprising the composition of the present invention and a pharmaceutically acceptable carrier.

[0027] In another aspect, a method for killing relevant cells in a subject is provided, comprising (i) administering an effective amount of the pharmaceutical composition of the present invention to the subject, thereby internalizing the nanoparticles into the relevant cells; and (ii) irradiating the relevant cells with a wavelength suitable for exciting barium titanate, thereby inducing death of the relevant cells.

[0028] In some embodiments, step (ii) comprises irradiating tissue of the subject comprising the cells of interest.

[0029] In some embodiments, the subject has a pathogen-related disease, a cell proliferation-related disease, or any combination thereof.

[0030] In some embodiments, the cells of interest include cancer cells, pathogenic cells, cells infected by pathogens, immune cells or activators thereof, or any combination thereof.

[0031] In another aspect, a method for treating a disease or disorder in a subject is provided, comprising (i) administering to the subject a therapeutically effective amount of a pharmaceutical composition of the present invention; and (ii) irradiating relevant tissue of the subject at a wavelength suitable for exciting barium titanate, thereby treating the disease or disorder.

[0032] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, exemplary methods and / or materials are described below. In the event of a conflict, the patent specification (including definitions) shall prevail. In addition, materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0033] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration only, as various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Certain embodiments of the present invention are described herein by way of example only with reference to the accompanying drawings. With specific reference now to the details of the accompanying drawings, it should be emphasized that the specific details shown are by way of example only and are provided for purposes of illustrative discussion of the embodiments of the present invention. In this regard, the description taken in conjunction with the accompanying drawings will enable those skilled in the art to understand the embodiments of the present invention.

[0035] Figure 1The scheme demonstrated the photodynamic effect in response to NIR light involving the conjugation of harmonic nanoparticles with photosensitizers (HNP-PS) using polyethylene glycol (PEG).

[0036] Figures 2A-2B The figure shows the BT (barium titanate), protoporphyrin IX (PPIX), curcumin (Crcmn), BT-PPIX (barium titanate conjugated with PPIX) and BT-Crcmn (barium titanate conjugated with curcumin) Figure 2A .Absorbance and Figure 2B .Fluorescence spectrum.

[0037] Figures 3A-3C The figure shows the near-infrared (800nm) femtosecond pulse wave laser beam line after excitation Figure 3A .BT (barium titanate), Figure 3B Protoporphyrin IX (PPIX) and Figure 3C Emission spectrum of curcumin (Crcmn); the box highlights the second harmonic generation, Figure 3B Comparison of protoporphyrin IX (PPIX) and BT+PPIX (barium titanate conjugated with PPIX) Figure 3C . Comparison of curcumin (Crcmn) and BT+Crcmn (barium titanate conjugated with curcumin).

[0038] Figures 4A-4B It is a bar chart showing Figure 4A .Survival rate of Staphylococcus aureus after dark treatment with BT (barium titanate) or PPIX (protoporphyrin IX) or Crcmn (curcumin) or HNP-PS conjugate. Figure 4B . Survival of Staphylococcus aureus after photodynamic treatment with pulsed NIR laser with BT+PPIX or BT+Crcmn or HNPs and PS alone. All irradiated samples were normalized to the survival rate of the laser alone at constant power. The cell counts remained constant across all labels. Error bars represent the standard error of 6 samples, each of which is an HNP-PS conjugate irradiated with laser, 4 samples of each HNP-PS conjugate in the dark, and 2 samples of each of the remaining. Each label represents a constant number of cells (200 μl, 10 3 -10 4 For details on the concentration of nanoparticles / photosensitizer (cells / ml) and nanoparticles / photosensitizer (20 μl, 400 μg / ml), see the Methods section.

[0039] Figures 5A-5B .Pulsed 800nm ​​laser excitation Figure 5A .BT+Crcmn and Figure 5B Spectral emission of BT+PPIX. Samples were used with the same concentration of the indicated perovskite or photosensitizer, or both, and irradiated at the same laser power.

[0040] Figure 6 Percentage of viability of MCF7 cells after PDT (photodynamic therapy) with BT+Crcmn or BT+PPIX as conjugate drugs using PEG100 and pulsed NIR laser excitation. Values ​​represent the mean and standard deviation of 8 measurements. DETAILED DESCRIPTION

[0041] According to some embodiments, a composition comprising a plurality of particles is provided, wherein each of the plurality of particles (also referred to herein as “nanoparticles of the present invention”) comprises: (i) a secondary generation (SHG) particle, (ii) a non-ionic water-soluble spacer, and (iii) a photosensitizer; and wherein the SHG nanoparticles are configured to emit a plurality of photons in a wavelength range between 360 nm and 450 nm; and the photosensitizer is a water-insoluble photosensitizer characterized by an absorbance range that at least partially overlaps the wavelength range; and wherein the photosensitizer is in operative communication with the SHG particles to allow excitation of the photosensitizer by the plurality of photons.

[0042] As used herein, the term "second harmonic generation particle" refers to a nanoparticle that absorbs photons and converts two absorbed photons into a single emitted photon (with double the energy). SHG can induce excitation of a photosensitizer operatively connected thereto.

[0043] In some embodiments, the nanoparticles of the present invention have a core in contact with a shell; wherein: the core includes an SHG particle configured to emit multiple photons in a wavelength range between 360 nm and 450 nm; and wherein the shell includes a water-soluble non-ionic spacer and a photosensitizer; and the photosensitizer is a water-insoluble photosensitizer characterized by an absorbance range that at least partially overlaps the wavelength range; the photosensitizer is separated from the core by the water-soluble non-ionic spacer to allow excitation of the photosensitizer by multiple photons.

[0044] In some embodiments, the nanoparticles of the present invention have a core in contact with a shell; wherein: the core comprises an SHG particle configured to emit multiple photons in a wavelength range between 360 nm and 450 nm; and wherein the shell comprises a water-soluble non-ionic spacer and a photosensitizer; and the photosensitizer is characterized by an absorbance range that at least partially overlaps with the wavelength range; the photosensitizer is separated from the core by the water-soluble non-ionic spacer to allow excitation of the photosensitizer by multiple photons.

[0045] In some embodiments, the nanoparticles of the present invention comprise a single SHG particle. In some embodiments, the nanoparticles of the present invention comprise a plurality of SHG particles. In some embodiments, the SHG particles are nanoparticles. In some embodiments, the SHG particles are characterized by an average particle size ranging between 10 nm and 200 nm, between 10 nm and 30 nm, between 10 nm and 50 nm, between 30 nm and 70 nm, between 50 nm and 100 nm, between 100 nm and 150 nm, between 150 nm and 200 nm, including any range therebetween.

[0046] In some embodiments, the SHG particles are or include perovskite. In some embodiments, the plurality of SHG nanoparticles are barium titanate, lithium niobate, potassium niobate, or any combination thereof. In some embodiments, the SHG particles are in a crystalline state. In some embodiments, the crystallinity is between 70% and 99.9%, between 70% and 80%, between 80% and 90%, between 90% and 99.9%, between 95% and 99.9%, including any range therebetween. As used herein, the term "perovskite" refers to any material having a crystalline corner-sharing BX6 octahedral lattice of the chemical formula ABX3. A represents a cation, B represents an anion, and X is typically an oxide, but may also be a halide.

[0047] In some embodiments, the SHG particles are characterized by an absorbance in the range of 600 nm to 900 nm, 600 nm to 650 nm, 650 nm to 700 nm, 700 nm to 750 nm, 750 nm to 800 nm, 800 nm to 850 nm, 850 nm to 900 nm, 900 nm to 950 nm, 950 nm to 1000 nm, or 1000 nm to 1200 nm. In some embodiments, the SHG particles are characterized by an absorbance in the range of 750 nm to 850 nm, 750 nm to 770 nm, 770 nm to 790 nm, 790 nm to 810 nm, 810 nm to 830 nm, or 830 nm to 850 nm, including any range therebetween. In certain embodiments, the SHG particles have at least one absorbance peak in the range of 600 nm to 900 nm.

[0048] It is speculated that the absorbance wavelength of SHG particles is in the wavelength range of maximum light penetration depth in biological tissue. Therefore, it is obvious that the particles of the present invention are generally located in the body of a subject. Accordingly, in order to effectively induce photodynamic therapy (PDT) inside the body of a subject (as opposed to generating PDT in the skin of a subject), the particles of the present invention (particularly SHG particles) need to be able to absorb light in the wavelength range of 600nm to 900nm, which is the wavelength range with maximum penetration depth in biological tissue.

[0049] As used herein, the term "plurality" includes any integer equal to or greater than 2. In some embodiments, the plurality includes at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10, or any value and range therebetween. Each possibility represents a separate embodiment of the present invention.

[0050] In some embodiments, the term "operable communication" includes a distance between the SHG particles and the photosensitizer that is sufficient to induce multiple photons emitted by the SHG particles to excite the photosensitizer. The term "distance" refers to the average distance between the SHG particles and the photosensitizer. In some embodiments, the distance between the SHG particles and the photosensitizer in the nanoparticles of the present invention is between 8A (angstroms) and 100nm, between 8A and 20nm, between 8A and 10nm, between 1nm and 5nm, between 1nm and 8nm, between 8nm and 10nm, between 10nm and 30nm, between 30nm and 50nm, between 50nm and 100nm, and up to 100nm, up to 80nm, up to 50nm, up to 30nm, up to 10nm, up to 80nm, up to 50nm, up to 30nm, up to 10nm, up to 8nm, up to 1nm, including any range in between. In some embodiments, the photosensitizer and the SHG particles are capable of operable communication, thereby inducing the production of reactive oxygen species (ROS).

[0051] In some embodiments, the term "operable communication" includes a distance suitable for inducing the production of ROS (by a photosensitizer) when the nanoparticles of the present invention are irradiated at a wavelength between 600 nm and 900 nm. In some embodiments, operable communication refers to a distance sufficient to induce the production of ROS, sufficient for use in photodynamic therapy. In some embodiments, the nanoparticles of the present invention are suitable for inducing a photodynamic response in cells. In some embodiments, the term "operable communication" includes that the quantum efficiency of the nanoparticles of the present invention is sufficient to induce the production of ROS. The term "quantum efficiency" refers to the ratio between the photons emitted by the nanoparticles of the present invention during irradiation and the photons absorbed by the photosensitizer. In some embodiments, the quantum efficiency of the nanoparticles of the present invention is between 10% and 90%, between 10% and 50%, between 10% and 80%, between 50% and 90%, between 30% and 90%, between 30% and 50%, between 10% and 30%, including any range therebetween.

[0052] It is speculated that when the SHG particles and the photosensitizer are in direct contact with each other, the SHG particles undergo non-radiative decay upon being excited, and thus the SHG particles are unable to induce excitation of the photosensitizer. Furthermore, it is speculated that when the distance between the SHG particles and the photosensitizer exceeds the distance disclosed herein, the photons emitted by the SHG particles do not reach the photosensitizer, and thus the photosensitizer is not excited by the SHG particles.

[0053] In some embodiments, the nonionic water-soluble spacer (also referred to herein as "spacer") within the nanoparticles of the present invention separates or distances the SHG particles and the photosensitizer so that the SHG particles and the photosensitizer are in operable communication with each other. In some embodiments, the SHG particles and the photosensitizer are separated by the nonionic water-soluble spacer so that the distance between the SHG particles and the photosensitizer within the nanoparticles of the present invention is as described above (e.g., between 8 Å and 100 nm). In some embodiments, the spacing is predetermined by the molecular weight of the spacer.

[0054] In some embodiments, the photosensitizer is a water-insoluble photosensitizer. In some embodiments, the photosensitizer is selected from protoporphyrin photosensitizers, curcumin photosensitizers or phthalocyanine photosensitizers, including any combination thereof. In some embodiments, the photosensitizer is characterized by absorbance at a wavelength between 360nm and 450nm, between 360nm and 390nm, between 360nm and 400nm, between 370nm and 380nm, between 370nm and 450nm, between 410nm and 430nm, between 400nm and 450nm, and any combination thereof.

[0055] In some embodiments, the spacer is a small molecule (less than 500Da, less than 300Da, less than 100Da), a polymer or an oligomer, including any combination thereof. In some embodiments, the spacer is characterized by an average length between 8A and 100nm, between 8A and 10nm, between 1nm and 10nm, between 1nm and 20nm, between 10nm and 20nm, between 5nm and 20nm, between 20nm and 40nm, between 40nm and 60nm, between 60nm and 80nm, between 80nm and 100nm, including any range therebetween, wherein the average length refers to the actual length of the spacer assembled in the nanoparticles of the present invention.

[0056] In some embodiments, the weight average molecular weight of the spacer is less than 1000 Da, less than 800 Da, less than 600 Da, less than 400 Da, less than 200 Da, less than 150 Da, and between 50 Da and 1000 Da, between 50 Da and 150 Da, between 75 Da and 125 Da, between 50 Da and 200 Da, between 200 Da and 400 Da, between 250 Da and 350 Da, between 400 Da and 600 Da, between 600 Da and 800 Da, between 800 Da and 1000 Da, including any ranges therebetween. As used herein, the term "weight average molecular weight" generally refers to a molecular weight measurement that depends on the proportion of polymer molecules according to their size.

[0057] In some embodiments, the spacer is characterized by a water solubility at a defined temperature (e.g., room temperature, 20°C to 100°C) of at least 50 mg / ml, at least 10 mg / ml, at least 20 mg / ml, at least 30 mg / ml, and between 10 mg / ml and 1000 mg / ml, between 10 mg / ml and 30 mg / ml, between 30 mg / ml and 70 mg / ml, between 50 mg / ml and 100 mg / ml, between 100 mg / ml and 200 mg / ml, between 200 mg / ml and 400 mg / ml, between 400 mg / ml and 600 mg / ml, between 600 mg / ml and 800 mg / ml, between 800 mg / ml and 1000 mg / ml, including any ranges therebetween.

[0058] Non-limiting examples of non-ionic water-soluble spacers include, but are not limited to, glycols (e.g., ethylene glycol (EG), propylene glycol, etc.); glycol (e.g., EG) oligomers (i.e., comprising between 2 and 5, 2, 3, 4, or 5 glycol (e.g., EG) monomer units), polyalkyl oxides (e.g., PEG, PPG, etc.), polyethylene glycol (PEG), polyvinyl alcohol, polyacrylamide, poly(propylene oxide), including any combination thereof.

[0059] In some embodiments, the non-ionic water-soluble spacer is selected from EG, EG oligomers, and PEG, and is characterized by an average MW between about 50 Da and about 300 Da, between about 50 Da and about 1000 Da, between about 50 Da and about 500 Da, between about 50 Da and about 200 Da, between about 50 Da and about 150 Da, between about 50 Da and about 400 Da, between about 50 Da and about 600 Da, including any ranges therebetween.

[0060] In some embodiments, the nanoparticles of the present invention consist essentially of SHG particles, spacers, and photosensitizers. In some embodiments, the w / w percentage of SHG particles, spacers, and photosensitizers within the nanoparticles of the present invention is at least 85%, at least 90%, at least 95%, at least 99%, and between 85% and 99%, between 85% and 90%, between 87% and 93%, between 90% and 95%, between 95% and 99%, including any ranges therebetween.

[0061] In some embodiments, the spacer and photosensitizer are bound to the SHG particles. In some embodiments, the binding is a non-covalent bond and / or a physical interaction. In some embodiments, the non-covalent bond is a hydrogen bond, a van der Waals bond, a dipole-dipole interaction, a hydrogen bond, a London force, or any combination thereof.

[0062] In some embodiments, the weight ratio between the photosensitizer and the spacer within the nanoparticles of the present invention is between about 1:100 and 1:4000, between about 1:150 and about 1:3500, between about 1:166 and 1:3333, between about 1:166 and 1:3000, between about 1:166 and 1:2000, between about 1:166 and 1:1000, between about 1:166 and 1:500, including any ranges therebetween.

[0063] In some embodiments, the molar ratio between the spacer and the SHG particles within the nanoparticles of the present invention is between 1:0.005 and 1:0.05, between 1:0.002 and 1:0.1, between 1:0.005 and 1:0.01, between 1:0.01 and 1:0.05, between 1:0.01 and 1:0.1, between 1:0.007 and 1:0.0085, between 1:0.005 and 1:0.01, between 1:0.007 and 1:0.01, between 1:0.07 and 1:0.09, between 1:0.01 and 1:0.05, including any ranges therebetween.

[0064] In some embodiments, the w / w percentage of SHG particles within the nanoparticles of the present invention is between 0.5% and 50%, between 0.5% and 10%, between 0.5% and 20%, between 15% and 25%, between 10% and 50%, between 10% and 30%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, including any ranges therebetween.

[0065] In some embodiments, the w / w percentage of SHG particles within the nanoparticles of the present invention is between 0.5% and 15%, between 0.5% and 2%, between 0.5% and 5%, between 0.5% and 10%, between 5% and 15%, between 10% and 15%, including any ranges therebetween.

[0066] In some embodiments, the w / w percentage of spacer within the nanoparticles of the present invention is between 40% and 99%, between 50% and 70%, between 60% and 99%, between 80% and 99%, between 90% and 99%, between 90% and 95%, between 95% and 99%, including any ranges therebetween.

[0067] In some embodiments, the weight ratio between the photosensitizer and the SHG particles is between 5:1 and 1:5, between 5:1 and 1:3, between 5:1 and 1:1, between 1:1 and 1:5, between 3:1 and 1:1, between 3:1 and 1:3, including any range therebetween. In some embodiments, the weight ratio between the photosensitizer and the SHG particles is between 2:1 and 1:2, or about 1:1, including any range therebetween.

[0068] In some embodiments, the nanoparticles of the present invention are referred to as stable if at least 80%, at least 85%, at least 90%, at least 95%, at least 99% of the particles by weight retain at least 90% of their particle size, including any range therebetween. In some embodiments, the nanoparticles of the present invention are referred to as stable if the particles by weight retain between 80% and 99%, between 80% and 85%, between 85% and 90%, between 90% and 95%, between 95% and 99%, including any range therebetween, of their particle size in solution. In some embodiments, the nanoparticles of the present invention are referred to as stable if at least 80%, at least 85%, at least 90%, at least 95%, at least 99% of the particles by weight substantially retain their chemical composition and / or substantially retain the ability to induce the production of ROS.

[0069] In some embodiments, the nanoparticles of the invention are referred to as stable when between 80% and 99%, between 80% and 85%, between 85% and 90%, between 90% and 95%, between 95% and 99% of the particles by weight retain at least 80% of their particle size in a solution (e.g., an aqueous solution) for a period of at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 24 hours, at least 2 days, at least 10 days, at least 20 days, at least 1 meter, at least 6 meters, at least 1 year, including any values ​​and ranges therebetween. Each possibility represents a separate embodiment of the invention.

[0070] In some embodiments, the nanoparticles of the present invention are referred to as stable when at least 80%, at least 85%, at least 90%, at least 95%, at least 99% of the particles by weight retain at least 90% of their particle size in a solution (e.g., an aqueous solution) for a period of at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 24 hours, at least 2 days, at least 10 days, at least 20 days, at least 1 meter, at least 6 meters, at least 1 year, including any values ​​and ranges therebetween. Each possibility represents a separate embodiment of the present invention.

[0071] In some embodiments, the nanoparticles of the present invention are referred to as stable when at least 80%, at least 85%, at least 90%, at least 95%, at least 99% of the particles by weight retain at least 80% of the initial photosensitizer content. In some embodiments, the plurality of nanoparticles of the present invention are referred to as stable when the particles by weight retain between 80% and 95%, between 80% and 85%, between 85% and 90%, between 90% and 95%, including any range therebetween, of the initial photosensitizer content.

[0072] In some embodiments, the nanoparticles of the present invention have a core in contact with an outer shell, wherein the core comprises SHG particles and the outer shell comprises a spacer and a photosensitizer. In some embodiments, the outer shell is in the form of a continuous layer of nonionic water-soluble spacer molecules. In some embodiments, the nonionic water-soluble spacer molecules are arranged in the form of a single layer within the outer shell. In some embodiments, the outer shell is in the form of multiple layers of nonionic water-soluble spacer molecules. In some embodiments, the outer shell is in the form of a double layer of nonionic water-soluble spacer molecules.

[0073] The term "continuous layer" or "layer" refers to a substantially homogeneous material of substantially uniform thickness that maintains its physicochemical properties (e.g., glass transition temperature, Young's modulus, elongation) throughout its dimensions (length and width dimensions). In some embodiments, each layer has a different physical structure and / or a different chemical composition. In some embodiments, each layer has the same physical structure and / or the same chemical composition. In some embodiments, the term "layer" refers to a layer of EG, EG oligomer, or PEG characterized by an average MW as disclosed herein.

[0074] In some embodiments, the nanoparticles of the present invention are core-shell nanoparticles. In some embodiments, the weight ratio between the shell and the core in a plurality of particles of the present invention is between 1:0.1 and 1:0.001, between 1:0.1 and 1:0.01, between 1:0.1 and 1:0.05, between 1:0.05 and 1:0.01, between 1:0.01 and 1:0.001, including any range therebetween. The term "shell" as used herein refers to the outer portion of the particle, which has a different composition than the core.

[0075] In some embodiments, the core is or includes SHG particles, or a plurality of (e.g., 2, 3, 4, 5) SHG particles. In some embodiments, the core is or includes barium titanate nanoparticles, lithium niobate nanoparticles, potassium niobate nanoparticles, or any combination thereof. In some embodiments, the core includes an outer portion facing the shell. In some embodiments, the outer portion of the core is in contact with or bound to the shell (i.e., the water-soluble non-ionic spacer disclosed herein). In some embodiments, the outer portion is bound to a spacer (e.g., an EG oligomer, or polyethylene glycol). In some embodiments, the spacer is bound to the core by non-covalent bonds and / or physical interactions. In some embodiments, the spacer is chemically adsorbed and / or physically adsorbed onto the core.

[0076] In some embodiments, the nanoparticles of the present invention do not have a photosensitizer in direct contact with the core. In some embodiments, the photosensitizer is not in direct contact with the core (e.g., barium titanate, and / or lithium niobate). In some embodiments, the photosensitizer is located in the shell of the nanoparticles of the present invention. In some embodiments, the photosensitizer is embedded in the shell of the nanoparticles of the present invention. In some embodiments, the photosensitizer is embedded in the shell of the nanoparticles of the present invention and is operably connected to the core, wherein "operably connected" is as described herein. In some embodiments, the core and photosensitizer are separated by a spacer. In some embodiments, the core and photosensitizer are separated by EG monomers, EG oligomers, or PEG, wherein the spacer is characterized by an average MW as disclosed herein (between 50Da and 1000Da, or between 50Da and 500Da). In some embodiments, the outer portion of the core is not bound to the photosensitizer.

[0077] In some embodiments, the nanoparticles of the present invention are substantially free of crosslinks. In some embodiments, the nanoparticles of the present invention are non-crosslinked nanoparticles.

[0078] In some embodiments, the inner portion comprises about 97%, about 98%, about 99%, about 99.9%, about 99.99%, or about 99.999% of the total weight and / or volume of the core. In some embodiments, the outer portion refers to the outer surface of the core. In some embodiments, the outer portion is in the form of a layer. In some embodiments, the inner portion and / or outer portion of the core are substantially free of organic compounds. In some embodiments, about 97%, about 98%, about 99%, about 99.9%, about 99.99%, or about 95% to 100%, between 95% and 99%, between 97% and 100%, or between 95% and 99.9% of the total weight of the core consists of SHG particles.

[0079] In some embodiments, the w / w ratio between the core and the shell in the nanoparticles of the present invention is between 3:1 and 1:3, between 3:1 and 1:2, between 1:3 and 1:1, between 2:1 and 1:3, between 1:1 and 1:3, and any range therebetween.

[0080] In some embodiments, the shell consists essentially of a spacer (e.g., PEG) and a photosensitizer. In some embodiments, about 97%, about 98%, about 99%, about 99.9%, about 99.99%, about 99.999%, or between 95% and 100%, between 95% and 99%, between 97% and 100%, between 95% and 99.9% of the total weight of the shell consists of a photosensitizer and a spacer. In some embodiments, the spacer is bound to the photosensitizer by non-covalent bonds (e.g., hydrogen bonds, van der Waals bonds, etc.) and / or physical interactions. In some embodiments, the photosensitizer is embedded in the spacer.

[0081] In some embodiments, the photosensitizer is stably bound to the spacer and / or core. In some embodiments, the term "stable" refers to the chemical stability of the bond (e.g., substantially no bond cleavage) under ambient conditions (temperature below 100° C., normal pressure or vacuum, and optionally ambient atmosphere) for a period of time between 1 day and 1 year, including any range therebetween.

[0082] In some embodiments, at least 80%, at least 90%, at least 93%, at least 95%, at least 97%, at least 99.9%, or 100% of the shell by weight and / or volume consists of the photosensitizer and the spacer associated therewith, including any ranges therebetween.

[0083] In some embodiments, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, at least 99.9%, or 100% by weight of the nanoparticles of the invention, including any range therebetween, is comprised of the core, the photosensitizer, and the spacer associated therewith.

[0084] In some embodiments, the nanoparticles of the present invention have a cubic geometry or shape. In some embodiments, the nanoparticles have an expanded or contracted shape. In some embodiments, the nanoparticles of the present invention do not have any characteristic geometry or shape. In some embodiments, the nanoparticles of the present invention have a spherical, quasi-spherical, cubic, hemicubic, quasi-ellipsoidal, contracted, concave, irregular shape or any combination thereof. It will be appreciated by those skilled in the art that the exact shape of each particle in a plurality of particles may be different from one another. In addition, the exact shape of the nanoparticles of the present invention can be derived from any of the above-mentioned geometric forms, so the shape of the particles does not fully conform to a specific geometric shape. It will be appreciated by those skilled in the art that the exact shape of the nanoparticles may deviate significantly (e.g., by a deviation of at least 5%, at least 10%, at least 20%) from a specific geometric shape (e.g., a cube or a sphere).

[0085] In some embodiments, the nanoparticles of the present invention are solid nanoparticles. In some embodiments, the nanoparticles are in colloidal form.

[0086] In another aspect, a composition comprising a plurality of nanoparticles is provided, wherein each of the plurality of nanoparticles comprises: (i) SHG particles, (ii) PEG, and (iii) a photosensitizer; wherein: the SHG particles and the photosensitizer are separated by the PEG; the photosensitizer is a water-insoluble photosensitizer characterized by an absorbance in a wavelength range between approximately 360 and 450 nm; and the SHG particles are barium titanate.

[0087] In some embodiments, PEG has an average molecular weight of less than 1000 Da, less than 800 Da, less than 600 Da, less than 400 Da, less than 200 Da, less than 150 Da, and between 100 Da and 2000 Da, between 100 Da and 400 Da, between 100 Da and 300 Da, between 200 Da and 400 Da, between 200 Da and 600 Da, between 200 Da and 1000 Da, between 250 Da and 350 Da, between 250 Da and 1500 Da, between 1000 Da and 2000 Da, including any range in between.

[0088] In some embodiments, the PEG molecular weight is between 280 Da and 320 Da.

[0089] In another aspect, a pharmaceutical composition is provided, comprising the composition of the present invention and a pharmaceutically acceptable carrier.

[0090] In some embodiments, a pharmaceutically acceptable carrier also refers to an excipient or adjuvant. As used herein, the term "carrier," "excipient," or "adjuvant" refers to any ingredient in a pharmaceutical composition that is not an active ingredient. As used herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic, inert solid, semi-solid liquid filler, diluent, encapsulating material, any type of formulation aid, or a simple sterile aqueous medium, such as saline. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution; ethanol and phosphate buffer solutions, and other nontoxic, compatible substances used in pharmaceutical formulations. Some non-limiting examples of materials that can be used as carriers herein include sugars, starches, cellulose and its derivatives, tragacanth powder, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols, alginic acid, pyrogen-free water, isotonic saline, phosphate buffered solution, cocoa butter (suppository base), emulsifiers, and other non-toxic pharmaceutically compatible materials used in other pharmaceutical formulations. Wetting agents and lubricants, such as sodium lauryl sulfate, as well as colorants, flavorings, excipients, stabilizers, antioxidants, and preservatives may also be present. Any non-toxic, inert, and effective carrier can be used to formulate the compositions described herein. Suitable pharmaceutically acceptable carriers, excipients, and diluents in this regard are well known to those skilled in the art, such as those described in The Merck Index, 13th Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, NJ (2001); the CTFA (Cosmetic, Toiletries, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, 10th Edition (2004); and the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management's "Inactive Ingredient Guide," all of which are incorporated herein by reference in their entirety. Examples of pharmaceutically acceptable excipients, carriers, and diluents useful in the present compositions include distilled water, physiological saline, Hartmann's solution, Ringer's solution, dextrose solution, Hank's solution, and DMSO.These additional inactive ingredients, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks, such as Goodman and Gillman: The Pharmacological Bases of The Diatrics, 8th ed., Gilman et al. Eds. Pergamon Press (1990); Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990); and Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins, Philadelphia, Pa. (2005), each of which is incorporated herein by reference in its entirety. The compositions of the present invention may also be contained in artificial structures, such as liposomes, ISCOMS, sustained-release particles, and other carriers that increase the half-life of the peptide or polypeptide in serum. Liposomes for the polypeptides of the present invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The choice of lipid generally depends on factors such as the size of the liposomes and their stability in blood. There are various methods for preparing liposomes, such as those reviewed in Coligan, JE et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York, and also in US Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

[0091] In some embodiments, the w / w concentration of the pharmaceutically acceptable carrier in the pharmaceutical composition is between 0.1% and 99%, between 0.1% and 1%, between 1% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 50%, between 50% and 60%, between 60% and 80%, or between 80% and 90%, including any range therebetween. Each possibility represents a separate embodiment of the present invention.

[0092] In some embodiments, the pharmaceutically acceptable carrier includes a buffer.

[0093] How to use

[0094] According to some embodiments, a method for making nanoparticles of the present invention is provided, wherein the method comprises contacting SHG particles, a nonionic water-soluble spacer, and a photosensitizer under appropriate conditions to form a plurality of nanoparticles of the present invention. In some embodiments, the method comprises obtaining a composition comprising SHG particles, a nonionic water-soluble spacer, and a photosensitizer, and an aqueous solvent.

[0095] In some, the concentrations of the SHG particles and the photosensitizer within the composition are independently between 100 ug / ml and 1000 ug / ml, between 100 ug / ml and 500 ug / ml, between 300 ug / ml and 500 ug / ml, between 300 ug / ml and 1000 ug / ml, between 200 ug / ml and 600 ug / ml, between 300 ug / ml and 700 ug / ml, between 400 ug / ml and 1000 ug / ml, between 350 ug / ml and 450 ug / ml, including any ranges therebetween.

[0096] In some, the concentration of the non-ionic water-soluble spacer in the composition is between 150ug / ml and 3000ug / ml, between 150ug / ml and 2500ug / ml, between 150ug / ml and 1000ug / ml, between 300ug / ml and 1000ug / ml, between 500ug / ml and 1500ug / ml, between 500ug / ml and 2500ug / ml, between 600ug / ml and 1500ug / ml, between 800ug / ml and 3000ug / ml, including any ranges therebetween.

[0097] In some embodiments, suitable conditions include exposing the composition to a temperature suitable for obtaining nanoparticles of the present invention. In some embodiments, suitable conditions further include exposing the composition to ultrasound. In some embodiments, suitable conditions include exposing the composition to a temperature suitable for obtaining nanoparticles of the present invention for a time period of between 0.5 min and 30 min, between 0.5 min and 5 min, between 5 min and 15 min, between 5 min and 20 min, between 10 min and 20 min, including any range therebetween. In some embodiments, the temperature suitable for obtaining nanoparticles of the present invention is between -10°C and 10°C, between -10°C and 0°C, between -5°C and 10°C, between -8°C and -2°C, between -10°C and 5°C, between -5°C and 0°C, including any range therebetween.

[0098] In some embodiments, the contacting is exposing the composition to ultrasound for a period of time between 0.5 min and 60 min, including any range therebetween, and the contacting temperature is between -10°C and 10°C, including any range therebetween.

[0099] In another aspect, a method for killing relevant cells in a subject is provided, comprising (i) administering to the subject an effective amount of the pharmaceutical composition of the present invention, thereby internalizing the composition into the relevant cells of the subject; and (ii) irradiating the relevant cells with a wavelength suitable for exciting SHG particles, thereby inducing cell death.

[0100] In some embodiments, step (ii) comprises irradiating tissue of the subject including the cells of interest.

[0101] The term "effective amount" or "therapeutically effective amount" refers to an amount that is effective at the dosage and time required to achieve the desired therapeutic effect. In some embodiments, the therapeutic outcome refers to the reduction or elimination of at least one symptom associated with the disease or disorder described herein. In some embodiments, the therapeutic outcome refers to at least 20%, at least 30%, at least 50%, at least 80% of the relevant cell death (e.g., by apoptosis). It will be apparent to one of ordinary skill in the art that the therapeutically effective amount of a molecule according to the present invention depends on the administration schedule, the unit dose of the administered molecule, whether the administered molecule is used in combination with other therapeutic agents, the patient's immune status and health status, the therapeutic activity of the administered molecule, and the judgment of the attending physician.

[0102] In some embodiments, the methods of the present invention are useful for inducing a photodynamic response in a subject in need thereof. In some embodiments, the methods of the present invention are useful for administering or inducing photodynamic therapy in a subject. In some embodiments, the methods of the present invention are useful for inducing a photodynamic response in a tissue in need thereof. In some embodiments, the methods of the present invention are useful for administering PDT in a subject in need thereof.

[0103] In some embodiments, the methods of the present invention are suitable for inducing photodynamic therapy in a relevant tissue in a subject in need thereof. In some embodiments, the methods are used to perform or induce photodynamic therapy in at least one relevant cell (or tissue).

[0104] In some embodiments, the subject is suffering from a pathogen-related disease (e.g., a microbial infection), a cell proliferation disease (e.g., cancer), or inflammation, or any combination thereof. In some embodiments, the related cells / or tissues include cancer cells / tissues, pathogenic cells, or mammalian cells / tissues infected by pathogens, or any combination thereof. In some embodiments, the pathogen is a unicellular organism. In some embodiments, the pathogen is selected from bacteria, fungi, eukaryotic parasites (e.g., unicellular parasites), or any combination thereof. In some embodiments, the pathogen is selected from, but not limited to, fungi, viruses, worms, protozoa, and prions, including any combination thereof.

[0105] In some embodiments, the pathogen-related disease is selected from, but not limited to, bacterial infection, viral infection, fungal infection, parasitic infection (eg, malaria, Leishmania, etc.).

[0106] In some embodiments, the subject is a mammal. In some embodiments, the mammal is a laboratory animal. Examples of laboratory animals include, but are not limited to, mice, rats, rabbits, hamsters, dogs, pigs, and monkeys. In some embodiments, the mammal is a mouse or rat. In some embodiments, the subject is a human subject.

[0107] In some embodiments, the compositions of the present invention are formulated for administration to a subject. In some embodiments, the method comprises administering the compositions of the present invention to a subject. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human. In some embodiments, the subject is in need of the composition. In some embodiments, the composition is used to treat a disease or condition in humans and other mammals. In some embodiments, the subject is in need of treatment. In some embodiments, the subject is suffering from a pathogen-related disease, a proliferative disease, or any combination thereof.

[0108] In some embodiments, the compositions of the present invention are formulated for administration to the relevant cells. In some embodiments, the compositions are formulated for systemic administration. In some embodiments, the compositions are formulated for intravenous (IV) administration. In some embodiments, the compositions are formulated for inhalation administration.

[0109] As used herein, the terms "administering," "administration," and similar terms refer to any method, in reasonable medical practice, of providing a composition comprising an active agent to a subject in a manner that provides a therapeutic effect. One aspect of the present subject matter is the intravenous administration of a therapeutically effective amount of the present subject matter composition to a patient in need thereof. Other suitable routes of administration may include parenteral, intravenous, subcutaneous, oral, intramuscular, intrathecal, inhalation, intracerebroventricular, intravitreal, transdermal, or intraperitoneal. In some embodiments, the composition is used in a therapeutic method. In some embodiments, the therapeutic method is a method of treatment. In some embodiments, the composition is used to treat a medical condition. In some embodiments, the medical condition is a condition, disease, or disorder.

[0110] In another aspect, a method for treating a disease or disorder in a subject is provided, comprising: (i) administering to the subject a therapeutically effective amount of a pharmaceutical composition of the present invention; and (ii) irradiating relevant tissue in the subject at a wavelength suitable for exciting SHG particles, thereby treating the disease or disorder in the subject. In some embodiments, the therapeutically effective amount of the pharmaceutical composition of the present invention is sufficient to accumulate in relevant cells and / or tissues of a subject in need thereof. In some embodiments, the accumulated amount is sufficient to induce a photodynamic response in the relevant cells and / or tissues.

[0111] In some embodiments, the photodynamic reaction comprises killing or eliminating at least one relevant cell (e.g., by apoptosis) in response to a trigger (irradiating the relevant cell / tissue with light of a wavelength suitable for exciting SH particles). In some embodiments, the photodynamic reaction comprises exciting a photosensitizer in response to irradiation, wherein the excitation of the photosensitizer is to induce the production of ROS in the relevant cell sufficient to kill or eliminate the relevant cell. In certain embodiments, the excitation of the photosensitizer is to induce the production of ROS in the relevant cell sufficient to induce apoptosis. Apoptosis can be assessed by determining the presence (or release) of pro-apoptotic factors in the relevant cell or in the relevant tissue.

[0112] In some embodiments, irradiating the tissue of interest comprises applying radiation having a wavelength between 600 nm and 900 nm, between 600 nm and 650 nm, between 650 nm and 700 nm, between 700 nm and 750 nm, between 750 nm and 800 nm, between 800 nm and 850 nm, between 850 nm and 900 nm, between 900 nm and 950 nm, between 950 nm and 1000 nm, between 1000 nm and 1200 nm, between 600 nm and 1200 nm, between 600 nm and 950 nm, between 600 nm and 1000 nm, between 750 nm and 850 nm, between 750 nm and 770 nm, between 770 nm and 790 nm, between 790 nm and 810 nm, between 810 nm and 830 nm, between 830 nm and 850 nm, including any range in between.

[0113] In some embodiments, irradiating the tissue of interest comprises applying radiation of a wavelength disclosed herein and a radiation dose sufficient to induce a photodynamic response in the cell / tissue of interest. In some embodiments, the radiation dose is sufficient to treat or eliminate at least one symptom associated with the disease in the subject. In some embodiments, the radiation dose does not exceed a safe dose, i.e., a dose that is below a dose associated with toxicity in the subject.

[0114] In some embodiments, the method further comprises repeating the applying step and / or the irradiating step. In some embodiments, the applying step and / or the irradiating step is repeated 2 times, 3 times, 4 times, 5 times, or between 2 times and 10 times, including any range therebetween.

[0115] In some embodiments, the method further comprises a preliminary step of selecting a subject suitable for treatment by the methods of the present invention. In some embodiments, the preliminary step is performed before the administering step (i.e., before treating the subject according to the methods disclosed herein). In some embodiments, the preliminary step comprises obtaining a sample from the subject, wherein the sample comprises a plurality of relevant cells (e.g., a blood sample or a biopsy sample); contacting the sample with a pharmaceutical composition or composition of the present invention; and irradiating the sample contacted with the composition / pharmaceutical composition of the present invention, wherein the irradiation is performed at a wavelength disclosed herein. In some embodiments, the preliminary step further comprises assessing the viability of the relevant cells after irradiation thereof, wherein a decrease in cell viability (at least a 20% decrease, at least a 30% decrease, or more) indicates that the subject is suitable for treatment.

[0116] In some embodiments, the pharmaceutical compositions of the present invention are in the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, gels, creams, ointments, foams, pastes, sustained-release formulations, and the like. In some embodiments, the pharmaceutical compositions of the present invention can be formulated as suppositories using conventional binders and carriers such as triglycerides, microcrystalline cellulose, tragacanth gum, or gelatin. Oral formulations can include standard carriers such as pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.

[0117] In some embodiments, the method comprises administering an effective amount of a pharmaceutical composition. In some embodiments, the effective amount is the human equivalent of a mouse dose between 0.1 mg / kg and 10 mg / kg body weight per day. In some embodiments, the human equivalent of a mouse dose depends on the route of administration. In some embodiments, the effective amount is the human equivalent of a mouse dose between 0.1 mg / kg and 10 mg / kg, between 0.1 mg / kg and 1 mg / kg, between 0.1 mg / kg and 0.5 mg / kg, between 0.5 mg / kg and 1 mg / kg, between 0.5 mg / kg and 10 mg / kg, between 0.5 mg / kg and 2 mg / kg, between 1 mg / kg and 5 mg / kg, between 5 mg / kg and 10 mg / kg body weight, including any value in between.

[0118] The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

[0119] General

[0120] Where a numerical range is provided, it is understood that each intervening value between the upper and lower limits of the range and between any other stated or intervening values ​​in the stated range, to the tenth of the lower limit, is encompassed herein unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed herein, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, the range excluding either or both of the limits is also encompassed herein.

[0121] As used herein, the term "consisting essentially of" means that a composition, method, or structure may include additional ingredients, steps, and / or parts, but only if the additional ingredients, steps, and / or parts do not materially alter the basic and novel characteristics of the claimed composition, method, or structure.

[0122] As used herein, the term "substantially" refers to at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or between 60% and 99.9%, between 70% and 80%, between 70% and 90%, between 80% and 90%, between 90% and 95%, between 95% and 99.9%, including any range or value in between.

[0123] As used herein, the term "about" when used in conjunction with a numerical value refers to the referenced value plus or minus 10% (±10%). For example, a length of about 1,000 nanometers (nm) refers to a length of 1,000 nm ± 100 nm.

[0124] It is noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "polynucleotide" includes a plurality of such polynucleotides, and reference to "the polypeptide" includes one or more polypeptides and equivalents thereof known to those of ordinary skill in the art, and so forth. It is further noted that claims may be drafted to exclude any optional element. Therefore, this statement is intended to serve as a reference basis for use of exclusive terminology such as "solely," "only," and the like when reciting claim elements or using a "negative" limitation.

[0125] Where a convention similar to "at least one of A, B, and C, etc." is used, generally speaking, such a construction is used in a sense that one of ordinary skill in the art would understand the convention (e.g., "a system having at least one of A, B, and C" would include, but is not limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). One of ordinary skill in the art would further understand that any antonymous conjunction and / or phrase that essentially sets forth two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one, either, or both of the terms. For example, the phrase "A or B" would be understood to include the possibility of "A" or "B" or "A and B."

[0126] It will be understood that certain features of the invention that are described for clarity in the context of individual embodiments may also be provided in combination in a single embodiment. Conversely, various features of the invention that are described for brevity in the context of individual embodiments may also be provided individually or in any suitable subcombination. All combinations of embodiments related to the invention are specifically encompassed by the invention and are disclosed herein, just as if each combination were individually and explicitly disclosed. Furthermore, all subcombinations of the various embodiments and elements thereof are also specifically encompassed by the invention and are disclosed herein, just as if each such subcombination were individually and explicitly disclosed.

[0127] Additional objects, advantages and novel features of the present invention will become apparent to those skilled in the art upon examination of the following examples, which are not intended to limit the present invention. In addition, each of the various embodiments and aspects of the present invention described above and as claimed below can find experimental support in the following examples.

[0128] Various embodiments and aspects of the present invention as delineated hereinabove and as described in the claims section below find experimental support in the following examples.

[0129] Example

[0130] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. These techniques are fully explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual,” Sambrook et al., (1989); “Current Protocols in Molecular Biology,” Volumes I-III Ausubel, RM, ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology,” John Wiley and Sons, Baltimore, Maryland (1989); Perbal, “A Practical Guide to Molecular Cloning,” John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA,” Scientific American Books, New York; Birren et al. (eds.), “Genome Analysis: A Laboratory Manual Series,” Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methods set forth in US Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook," Volumes I-III Cellis, JE, ed. (1994); "Culture of Animal Cells—A Manual of Basic Technique," Freshney, Wiley-Liss, NY (1994), 3rd edition; "Current Protocols in Immunology," Volumes I-III Coligan JE, ed. (1994); Stites et al.(eds), "Basic and Clinical Immunology" (8th ed.), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference. Other general references are also provided in this document.

[0131] Example 1

[0132] Conjugates of nanoparticles and photosensitizers

[0133] The synthesis of exemplary nanoparticles of the present invention was carried out by mixing 6 mg of barium titanate (BT) (467634, Sigma-Aldrich, USA) with 6 mg of photosensitizer protoporphyrin IX (P8293-1G, Sigma-Aldrich, USA) or curcumin (C1386, Sigma-Aldrich, USA) in 15 ml of 6% HCl dissolved in distilled water. PEG-300 (PEG) (91462, Sigma-Aldrich, USA) was mixed and sonicated on ice to obtain photodynamic therapy (PDT) particles with a concentration of 400 μg / ml BT+PPIX particles or BT+Crcmn particles ( Figure 1 Subsequently, the sample was filtered through a 0.22 μm PVDF membrane (FPV-203-013, JetBiofil, China).

[0134] Although BT harmonic nanoparticles are easy to synthesize, stabilizers are required in a hydrated environment to prevent precipitation. In order for efficient energy transfer to occur upon photoactivation, the HNP and PS must be relatively close together. By attaching PEG phospholipids to the nanoparticles, a hydrophobic environment is created around the HNPs to facilitate drug delivery via lipid carriers and enhance PS delivery. In addition, as the degree of hydrophobicity increases, the affinity of the PS for uptake by membrane-bound cells and tumor tissues also increases. The PEGylated HNPs are then loaded with PS ( Figure 1 ) and effectively enhance their cellular uptake. PEGylation also improves the colloidal properties of both HNPs and PS.

[0135] Characterization of harmonic nanoparticle-photosensitizer (HNP) conjugates

[0136] In our experiments, the typical sizes of BaTiO3 HNPs prepared for conjugation by sonication and filtration were 53 ± 9 nm for BT + PPIX and 52 ± 9 nm for BT + Crcmn, respectively, which are consistent with the ideal size of BaTiO3 HNPs of 55 nm for SHG efficiency.

[0137] The spectral properties of perovskite barium titanate (BT) harmonic nanoparticles conjugated with FDA-approved protoporphyrin IX (PPIX) or curcumin as PS using polyethylene glycol (PEG) were analyzed. Figure 2A ). PPIX itself shows absorbance saturation at 369-400nm and a broad peak at 365nm. Curcumin itself shows absorbance saturation at 415-430nm and a peak at 424nm. BT itself does not show any absorbance in the range of 350-400nm. After conjugation with PPIX, the absorbance curve of BT shows a small peak near 400nm, which corresponds to the absorbance curve of the photosensitizer PPIX itself, indicating the proximity of the particles. Conjugation with curcumin causes the absorbance curve of BT to shift, and in addition to the reported 424nm peak of curcumin alone, another peak appears at 340nm.

[0138] BT itself shows a fluorescence emission maximum at 463 nm after excitation at 400 nm. Figure 2B PPIX itself exhibits two fluorescence emission maxima at 462 nm and 624 nm after excitation at a wavelength of 400 nm ( Figure 2B After conjugation with BT, the fluorescence emission curve of PPIX shows a small peak near 463nm, which corresponds to the fluorescence emission curve of the photosensitizer PPIX itself, and an enhanced peak appears at 624nm, indicating that the nanoparticles are close to the photosensitizer. Curcumin itself shows a fluorescence emission maximum at 540nm under excitation of 400nm wavelength ( Figure 2B BT conjugation did not affect the fluorescence emission curve of curcumin, which showed a peak at 540 nm similar to that of the photosensitizer itself.

[0139] Example 2

[0140] Electron Optics

[0141] Spectral analysis—Spectral analysis was performed using a V-730 UV-visible spectrophotometer (Jasco, USA) and the Spectra Manager TM The analysis was performed using a spectral analysis software package (Jasco, USA).

[0142] Laser Settings - Use Laser was generated by a Pro s Series 5SJSPG (Spectra physics, USA) laser device to produce 546 nm continuous wave laser light, which was generated by an ultrafast oscillator. A Scientifc 20 (Femtolasers, Inc.) was used to generate a near-infrared (800 nm) pulsed wave (pulse frequency 76.9 MHz) beamline. The beamline was appropriately configured using a beam splitter to provide real-time power readings. Power measurements were recorded using a compact power meter PM100D (Thorlabs, Inc.) equipped with an S370C thermal power head (Thorlabs, Inc.).

[0143] Cell culture

[0144] Staphylococcus aureus (ATCC 25923) was grown on brain heart agar plates (BHA, Acumedia, Lansing, MI, USA) for 24 hours. The grown cells were transferred to brain heart broth (BH, Acumedia, Lansing, MI, USA) and cultured at 37 ± 1°C with shaking at 170 rpm until the absorbance at 660 nm reached A = 0.10 ± 0.02, equivalent to 10 8 The final concentration was 10 cells / ml, and then diluted appropriately with commercially available sterile 0.9% saline solution to 10 3 -10 4 The final concentration of cells / ml was used for light and dark phototoxicity tests.

[0145] Bright light toxicity

[0146] 200 μl of bacterial suspension (10 3 -10 4 Cells (cells / μl) were incubated with 20 μl of PDT nanoparticle conjugate (400 μg / ml) and oscillated under laser light (800 nm, 232-228 mW, 76.9 MHz) for 10 minutes. Subsequently, a 100 μl aliquot of each sample was spread onto a BHA plate using a Drigalski spreader and incubated at 37°C for 24 hours. CFU were counted using a Scan 500 colony counter.

[0147] Dark phototoxicity

[0148] 200 μl of cell suspension (10 3 -10 4Cells were collected from 20 μl of PDT nanoparticle conjugate (400 μg / ml) in sterile saline solution and incubated with shaking in the dark for 30 minutes. Subsequently, a 100 μl aliquot of each sample was spread onto a BHA plate using a Drigalsky spreader and incubated at 37°C for 24 hours. Colony-forming units (CFU) were counted using a Scan 500 colony counter (Interscience, Saint-Nom-la-Breteche, France).

[0149] Second harmonic generation of harmonic nanoparticles using pulsed NIR irradiation and activated emission of conjugated photosensitizers

[0150] When femtosecond pulse laser was irradiated at 800nm ​​wavelength, BT itself showed an emission peak at 400nm wavelength, which indicated that the harmonic nanoparticles generated the second harmonic ( Figure 3A ), while the unconjugated photosensitizer itself did not show any such reaction. After PPIX was conjugated with BT harmonic nanoparticles, a clear emission peak at 641.5 nm was activated, while this emission peak was absent when it was not conjugated ( Figure 3B Similarly, when Crcmn was conjugated with BT harmonic nanoparticles, an emission peak at 559.8 nm was activated, while this emission peak was absent when it was not conjugated ( Figure 3B ).

[0151] NIR photodynamic effects of HNP-PS conjugates on Staphylococcus aureus

[0152] Dark toxicity tests of the prepared HNP-PS conjugates showed that the survival rates of pathogenic Staphylococcus aureus were reduced by 28.4 ± 3.0% and 44.1 ± 4.2% after 30 min of dark incubation with BT + PPIX or BT + Crcmn, respectively, compared with the untreated control ( Figure 4A Compared to the control, treatment with BT alone or PPIX alone had no significant effect on survival in dark conditions. However, Crcmn alone showed a 14.2 ± 1.1% increase in survival compared to the control.

[0153] Compared with the untreated control, 20 μl (concentration of 400 μg / ml) BT+PPIX or BT+Crcmn was irradiated with pulsed NIR (800 nm) laser for 10 minutes to induce photodynamic effect on the treated 200 μl Staphylococcus aureus samples (concentration of 10 3 -10 4 cells / ml) decreased by 77.3±9.7% and 38.4±6.1% ( Figure 4B ).

[0154] Laser exposure alone reduced the survival rate of treated samples by 28.8 ± 0.1%. Laser-exposed BT increased the survival rate of treated samples by 24.7 ± 0.4%. PPIX alone, exposed to the laser for 10 minutes, had no significant effect on the survival rate of S. aureus, decreasing it by 20.4 ± 2.5%, similar to laser irradiation alone. Curcumin alone, exposed to the laser for 10 minutes, increased the survival rate of treated samples by 20.2 ± 1.4%. This suggests that conjugation to HNPs activates the photosensitizer within the NIR spectral range, resulting in the desired antibacterial photodynamic effect.

[0155] The average power of the laser exposure was measured during the experiment. The readings were normalized to provide similarity in energy transfer between the nanoparticle and conjugate samples during the antimicrobial photodynamic effect assay.

[0156] These studies suggest that simply coupling SHG-capable nanoparticles stabilized in suspension with conventional PSs can directly enhance the therapeutic efficacy of PDT without the need for new chemical mixtures or compositions.

[0157] Furthermore, by incorporating appropriate SHG-capable BT harmonic nanoparticles into the PDT process, commonly used photosensitizers that traditionally respond only to the visible light spectrum (e.g., protoporphyrin IX and curcumin, respectively) can be made photodynamically responsive to the deeper penetrating near-infrared light.

[0158] Furthermore, we demonstrated that protoporphyrin IX was significantly more effective than curcumin for SHG-mediated near-infrared photodynamic therapy using a visible light-responsive photosensitizer.

[0159] Example 3

[0160] Effect of (PEG) Ligand Length on SHG and PDT Effects

[0161] According to the above synthesis process, the conjugation between BT and photosensitizer (curcumin or protoporphyrin IX, BT+Crcmn or BT+PPIX, respectively) was carried out in the presence of five different ligand lengths. Five ligands, ethylene glycol monomers PEG100, PEG200, PEG300 and PEG400, and their SHG capabilities were tested. The spectral emission of the five different BT+Crcmn and BT+PPIX conjugates under 800nm ​​pulsed laser excitation was detected ( Figure 5A and Figure 5B ). In both cases, the conjugate including PEG100 showed the best spectroscopic performance.

[0162] MCF7 cells were then cultured with BT+Crcmn and BT+PPIX containing PEG100 for 1 h. In these two cases, the cell viability decreased by 73% and 64%, respectively. Figure 6 ). Therefore, it can be speculated that the nanoparticles of the present invention can be successfully used to implement or induce PDT in a subject in need thereof (e.g., for the treatment of proliferative diseases or infectious diseases).

[0163] Furthermore, the present inventors have successfully synthesized lithium niobate-based nanoparticles of the present invention (using PEG as a water-soluble spacer and protoporphyrin as a photosensitizer), as disclosed above for barium titanate-based particles. The lithium niobate-based nanoparticles exhibit similar spectral properties to barium titanate (lithium niobate excitation induces photosensitizer excitation, which is speculated to result in ROS generation). Therefore, it is speculated that the perovskite-based nanoparticles of the present invention are suitable for implementing or inducing PDT in a subject in need thereof (e.g., for treating proliferative diseases or infectious diseases).

[0164] Although the present invention has been described in conjunction with its specific embodiments, many alternatives, modifications and variations will be apparent to those skilled in the art. Therefore, the present invention is intended to encompass all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

Claims

1. A composition comprising a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises (i) a second harmonic generation (SHG) particle, (ii) a non-ionic water-soluble spacer, and (iii) a photosensitizer; wherein: The SHG particles are configured to emit a plurality of photons in a wavelength range between 360 nm and 450 nm; The photosensitizer is a water-insoluble photosensitizer, characterized in that the absorbance range at least partially overlaps with the wavelength range; And wherein the photosensitizer is in operable communication with the SHG particles to allow the plurality of photons to excite the photosensitizer. 2 . The composition of claim 1 , wherein the operable communication comprises a distance between the SHG particles and the photosensitizer suitable for the multiple photons to excite the photosensitizer.

3. The composition of claim 2, wherein the SHG particles and the photosensitizer are separated by the non-ionic water-soluble spacer; and wherein the distance is predetermined by the molecular weight of the water-soluble spacer.

4. A composition according to claim 3, wherein the molecular weight is between 50 Da and 1000 Da.

5. The composition according to any one of claims 1 to 4, wherein the water-soluble spacer comprises ethylene glycol (EG), EG oligomer or polyethylene glycol (PEG).

6. The composition according to any one of claims 1 to 5, wherein the SHG nanoparticles are selected from barium titanate, lithium niobate and potassium niobate, or any combination thereof.

7. The composition according to any one of claims 1 to 6, wherein the photosensitizer is selected from a curcuminoid photosensitizer, a porphyrin photosensitizer or a phthalocyanine photosensitizer, and any combination thereof.

8. The composition according to claim 7, wherein the porphyrin-based photosensitizer is protoporphyrin IX, including any salt thereof.

9. A composition comprising a plurality of nanoparticles, wherein each of the plurality of nanoparticles has a core in contact with an outer shell; wherein: The core includes a SHG particle configured to emit a plurality of photons within a wavelength range between 360 nm and 450 nm; The shell includes a water-soluble nonionic spacer and a photosensitizer; and The photosensitizer is a water-insoluble photosensitizer, characterized in that the absorbance range at least partially overlaps with the wavelength range; The photosensitizer is separated from the core by a water-soluble non-ionic spacer to allow the plurality of photons to excite the photosensitizer.

10. The composition according to claim 9, wherein the photosensitizer is selected from a curcuminoid photosensitizer or a porphyrin photosensitizer, and any combination thereof.

11. The composition according to claim 10, wherein the porphyrin-based photosensitizer is protoporphyrin IX, including any salt thereof.

12. The composition according to any one of claims 9 to 11, wherein the average molecular weight of the water-soluble non-ionic spacer is between 50 Da and 1000 Da.

13. The composition according to any one of claims 9 to 12, wherein the water-soluble non-ionic spacer comprises ethylene glycol (EG), EG oligomers or polyethylene glycol (PEG).

14. The composition according to any one of claims 1 to 13, wherein the weight ratio of the photosensitizer to the non-ionic water-soluble spacer in the composition is between 1:150 and 1:3500.

15. The composition according to any one of claims 1 to 14, wherein the weight ratio between the photosensitizer and the SHG particles in the composition is between 5:1 and 1:

5.

16. The composition of any one of claims 1 to 15, wherein each of the plurality of nanoparticles is suitable for inducing a photodynamic response in a cell.

17. A composition comprising a plurality of nanoparticles, wherein each of the plurality of nanoparticles comprises: (i) SHG particles, (ii) PEG and (iii) a photosensitizer; wherein: The SHG particles and the photosensitizer are separated by the PEG; The photosensitizer is a water-insoluble photosensitizer characterized by an absorbance at a wavelength ranging between about 360 nm and 450 nm; The SHG particles are barium titanate; and The PEG is characterized by an average molecular weight between 50 Da and 1000 Da.

18. The composition of claim 17, wherein the photosensitizer is selected from protoporphyrin IX and curcumin, including any salts thereof; and the PEG is characterized by an average molecular weight between about 280 Da and 320 Da.

19. A pharmaceutical composition comprising the composition according to any one of claims 1 to 18 and a pharmaceutically acceptable carrier.

20. A method for killing relevant cells in a subject, comprising (i) administering to the subject an effective amount of the pharmaceutical composition of claim 19, thereby internalizing the nanoparticles into the relevant cells; and (ii) irradiating the relevant cells with a wavelength suitable for exciting the barium titanate, thereby inducing death of the relevant cells.

21. The method of claim 20, wherein step (ii) comprises irradiating tissue of the subject including the cells of interest.

22. The method of claim 20 or 21, wherein the subject suffers from a pathogen-related disease, a cell proliferation-related disease, or any combination thereof.

23. The method according to any one of claims 20 to 22, wherein the relevant cells comprise cancer cells, pathogenic cells, cells infected by pathogens, immune cells or activators thereof, or any combination thereof.

24. A method for treating a disease or disorder in a subject, comprising: (i) administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 19; and (ii) irradiating relevant tissue of the subject at a wavelength suitable for exciting the barium titanate, thereby treating the disease or disorder.